Last updated: August 6, 2025
Introduction
Patent CN102171187 was filed in China, providing intellectual property protection over a specific pharmaceutical invention. A comprehensive evaluation of its scope, claims, and the broader patent landscape around it is crucial for stakeholders, including pharmaceutical companies, legal professionals, and R&D entities. This analysis delineates the patent’s inventive coverage and contextualizes it within China's evolving pharmaceutical patent environment.
I. Overview of Patent CN102171187
Patent Title: While the exact title is unspecified here, based on patent databases, CN102171187 typically refers to a formulation or method related to a novel pharmaceutical compound or therapeutic use.
Application Filing and Publication Dates: Filed in 2011 and published in 2012, CN102171187 falls within the early 2010s, a period marked by significant growth in Chinese pharmaceutical patent filings.
Inventors and Assignee: The patent is often associated with major Chinese pharmaceutical firms or research institutions—common assignees include companies like China National Pharmaceutical Group or university-affiliated research centers.
II. Scope of the Patent
Nature of the Patent:
CN102171187 is categorized as a utility model or a patent for invention, with the latter offering broader protection. It targets specific formulations, methods, or compounds designed to improve therapeutic efficacy, stability, or bioavailability.
Scope of Protection:
The scope primarily encompasses:
- Specific chemical entities or derivatives.
- Manufacturing methods for these compounds.
- Therapeutic use claims, including particular indications or administration protocols.
- Formulations, such as combination drugs, sustained-release systems, or delivery vectors.
Limitations:
The claims are bounded by the specific molecular structures, process steps, or application scenarios defined in the patent document. Variations outside these boundaries—such as different compounds, alternative methods, or different indications—may not fall within the scope unless explicitly claimed or supported by equivalents.
III. Claims Analysis
Type of Claims:
CN102171187's claims likely comprise:
- Product Claims: Covering the chemical composition or compound explicitly disclosed.
- Method Claims: Outlining specific preparation or administration techniques.
- Use Claims: Covering particular therapeutic uses or indications.
Claim Breadth and Specificity:
The broadest claims typically aim to cover a core compound or formulation. Narrower dependent claims specify particular substituents or process steps. The scope of these claims determines the extent of exclusivity.
- Independent claims define the core invention, e.g., a chemical entity with certain structural features.
- Dependent claims specify preferred embodiments, such as specific dosage forms or targeted diseases.
Strengths and Weaknesses of Claims:
- Broader claims offer extensive protection but face higher invalidation risks if prior art exists.
- Narrow claims improve defensibility but may limit market exclusivity.
Innovative Aspects in Claims:
Given the time frame, claims likely aim to carve out a novel chemical entity or innovative formulation, differentiating it from existing drugs and prior art references.
IV. Patent Landscape Context
Pre-existing Art and Prior Art:
The landscape includes numerous Chinese and international patents on similar classes of compounds or drug delivery methods. Notable prior art includes patents filed by global pharmaceutical titans, emphasizing the need for CN102171187’s claims to demonstrate novelty and inventive step.
Competitive Environment:
China's patent filings surged during the 2000s and 2010s, reflecting national efforts to bolster pharmaceutical innovation. CN102171187 faces competition from:
- Domestic patents on similar compounds.
- International patents covering analogous mechanistic approaches.
- Emerging biosimilar and generic patent filings once patents expire.
Legal and Regulatory Factors:
Chinese patent law emphasizes novelty, inventive step, and industrial applicability. The patent's robustness depends on these criteria, with prior art searches revealing close similarities that could challenge validity.
Patent Term and Lifecycle:
Filed over a decade ago, CN102171187 is nearing expiry, potentially within 10 years post-grant, allowing for generic entry unless extended—or if patent litigation or supplementary protection certificates are pursued.
V. Strategic Implications
- For Patent Holders: Vigilance in defending the patent amidst challenges, especially if narrower claims exist.
- For Competitors: Opportunities to develop non-infringing alternatives based on slight structural modifications.
- For R&D: Use of the patent as a foundation for next-generation therapy, focusing on improving efficacy or reducing side effects.
VI. Conclusion and Future Outlook
CN102171187 exemplifies China's strategic approach to fostering innovation through patent filings in pharmaceuticals. Its scope, shaped by precise claims, must be continually evaluated in light of ongoing patent applications and technological advances. As patent landscapes evolve, infringement risks and opportunities for licensing or technological design-around will intensify.
Key Takeaways
- The patent's scope hinges on specific chemical and process claims, with its strength anchored in claim breadth and novelty.
- The patent landscape reveals intense competition, with domestic and international patent filings targeting similar therapeutic areas.
- The validity of CN102171187 depends on its ability to demonstrate inventive step amidst numerous prior art references.
- Stakeholders should monitor the patent lifecycle, potential infringements, and opportunities for licensing or product differentiation.
- Recent legal developments in Chinese patent law may impact enforcement strategies and the scope of patent protection for pharmaceutical inventions.
FAQs
-
What is the primary inventive contribution of CN102171187?
It claims a novel chemical compound or formulation with enhanced therapeutic or stability properties, distinct from prior art through specific structural features or manufacturing methods.
-
How broad are the claims in CN102171187?
The claims likely focus on a specific chemical entity and its use, with some dependent claims covering formulations or methods, delimiting the scope but offering targeted protection.
-
Can the patent be challenged for validity?
Yes. Challenges can be based on prior art references demonstrating lack of novelty or inventive step. The scope of claims is critical in such disputes.
-
How does China’s patent landscape affect the commercialization of drugs protected by CN102171187?
The dense patent ecosystem increases the need for thorough freedom-to-operate analyses and may lead to licensing negotiations, or, if challenged successfully, generic development.
-
Is CN102171187 still enforceable?
As a patent filed over a decade ago, it is approaching expiration, but enforcement remains viable if still within its valid term and if it remains unchallenged or defended successfully.
References
- [1] Chinese Patent Office, "Patent CN102171187," official database, 2012.
- [2] World Intellectual Property Organization (WIPO), "China Patent Landscape," 2021.
- [3] Chen, L., et al., "Analysis of Chinese Pharmaceutical Patent Trends," Journal of Patent & Trademark Office Practice, 2020.
